Loading
Cutia Therapeutics - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Zhang Lele, was filed 08 Nov 2024.
Cutia Therapeutics - B: what insiders have been doing
Cutia Therapeutics - B, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to HKEX. From 22 October 2025 to 22 October 2026, the disclosure feed for Cutia Therapeutics - B logged 23 filings by 3 insiders.
No insider bought on the market over the period, while 1 insider filed 17 sales totalling €473k. The largest single trade was a sale of €114k by Zhang Lele, published on 2 October 2026, equal to 0.27% of the market capitalisation.
Compared with its exchange (1,314 companies, median 4 filings), a count of 23 filings is above the norm. Over the whole record (from 2023), the tally stands at 7 purchases and 17 sales.
Typically, a trade is published a median of 3 days after it takes place. Until a filing is published, the market cannot know about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from HKEX. Past trades are no guide to future returns.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€181,618
7 ops. · all time
Sell Volume
€472,648
17 ops. · all time
Who traded when
BuySaleZhang Lele1 buy17 sales
Since the insiders bought
- -33.5%Entry HK$9.41 · Close at T+365 HK$6.26
- -33.4%Entry HK$13.34 · Close at T+365 HK$8.88
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,523 of 26,286 companies
22.3
score / 100
Value1
Quality44
FCF yld-116%
Earn yld-130%
EV/EBITDA·
ROE-38%
Gross mgn58%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$0.72
Analyst consensus
1 analysts1.00/5
HK$7.72Target HK$7.72(+979%)HK$7.72
Income statement
RevenueHK$336.2M
Gross profitHK$195.8M58% margin
EBITDA-HK$287.1M-85% margin
Net income-HK$340.2M-84.6% margin
Valuation
PER (forward)5.1x
P/Book0.3x
Beta0.78
Balance sheet & cash
Market capHK$266.8M
Total debtHK$317.4M
Free Cash Flow-HK$303M
Debt / Equity39%
Profitability & ownership
ROE-38.3%
ROA-14.1%
% insiders25.8%
% institutions60.7%
Last declaration on 16 October 2026
Declarations34 total
91,000 shares@ HK$0.81780.024% mcap1.8% of flowShareXHKGHKEX:DA20261016E00408
671,600 shares@ HK$0.6260.14% mcap10.1% of flowShareXHKGHKEX:DA20261016E00413
1,173,000 shares@ HK$0.67680.26% mcap19.1% of flowShareXHKGHKEX:DA20261016E00412
118,200 shares@ HK$0.75110.029% mcap2.1% of flowShareXHKGHKEX:DA20261016E00411
90,400 shares@ HK$0.79220.023% mcap1.7% of flowShareXHKGHKEX:DA20261016E00410
68,200 shares@ HK$0.82150.018% mcap1.3% of flowShareXHKGHKEX:DA20261016E00409
258,600 shares@ HK$0.90550.073% mcap8.8% of flowShareXHKGHKEX:DA20261009E00554
229,600 shares@ HK$0.97610.070% mcap8.4% of flowShareXHKGHKEX:DA20261009E00552
130,600 shares@ HK$0.88890.036% mcap4.4% of flowShareXHKGHKEX:DA20261009E00555
81,400 shares@ HK$0.94990.024% mcap2.9% of flowShareXHKGHKEX:DA20261009E00553
91,000 shares@ HK$0.95970.023% mcap8.6% of flowShareXHKGHKEX:DA20260930E00363
4,624,153 sharesShareXHKGHKEX:DA20260930E00371
3,150,000 sharesShareXHKGHKEX:DA20260930E00381
1,302,800 shares@ HK$0.77840.27% mcap49.9% of flowShareXHKGHKEX:DA20260930E00368
653,800 shares@ HK$1.0070.21% mcap15.6% of flowShareXHKGHKEX:DA20260925E00252
113,400 shares@ HK$1.0640.039% mcap2.8% of flowShareXHKGHKEX:DA20260925E00243
136,800 shares@ HK$1.08420.047% mcap3.5% of flowShareXHKGHKEX:DA20260925E00207
5,200 shares@ HK$1.17920.0020% mcap0.1% of flowShareXHKGHKEX:DA20260924E00610
200 shares@ HK$1.200.0001% mcap0.0% of flowShareXHKGHKEX:DA20260924E00609
187,500 shares0ShareXHKGHKEX:DA20260703E00308
604,707 shares0ShareXHKGHKEX:DA20260703E00298
3,797,295 sharesShareXHKGHKEX:DA20251106E00414
2,499,519 sharesShareXHKGHKEX:DA20251106E00413
9,000,000 sharesShareXHKGHKEX:DA20241115E00361
1,157,500 sharesShareXHKGHKEX:DA20241108E00300
25 of 34 declarations
About Cutia Therapeutics - B
Cutia Therapeutics - B is a company focused on developing innovative treatments for chronic diseases. It specializes in research and the advancement of therapeutic solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
